PJP · ARCA · ETF
Invesco Pharmaceuticals ETF (PJP) Price, Holdings & Fees
Invesco Pharmaceuticals ETF (PJP) closed at $588.81 on Oct 9, 2026, down 1.23% from the previous close of $596.16.
Share price, past year
1Y +34.79%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $588.81 |
| Sep 30, 2026 | $595.59 |
| Aug 31, 2026 | $597.40 |
| Jul 31, 2026 | $595.83 |
| Jun 30, 2026 | $561.75 |
| May 29, 2026 | $540.71 |
| Apr 30, 2026 | $511.67 |
| Mar 31, 2026 | $542.63 |
| Feb 27, 2026 | $522.69 |
| Jan 30, 2026 | $507.12 |
| Dec 31, 2025 | $486.58 |
| Nov 28, 2025 | $465.62 |
| Oct 31, 2025 | $463.98 |
Key statistics
- Expense ratio
- 0.57%
- as of Aug 31, 2025
- Net assets
- $472.1M
- as of Jul 31, 2026
- Holdings
- 33
- as of Jul 31, 2026
- 52-week range
- $436.85 – $606.13
Invesco Pharmaceuticals ETF's expense ratio is 0.57%: $57.00 a year on $10,000 invested.
Holdings
Invesco Pharmaceuticals ETF held 33 investments worth $472.10M as of Jul 31, 2026. Its largest holding was Invesco Private Prime Fund, at 7.93% of the fund.
| # | Holding | % of fund | Value |
|---|---|---|---|
| 1 | Invesco Private Prime Fund | 7.93% | $37.43M |
| 2 | Abbott Laboratories | 5.67% | $26.78M |
| 3 | AbbVie Inc. | 5.48% | $25.86M |
| 4 | Amgen Inc. | 5.33% | $25.17M |
| 5 | Johnson & Johnson | 5.18% | $24.45M |
| 6 | Merck & Co., Inc. | 5.06% | $23.87M |
| 7 | Eli Lilly and Co. | 5.02% | $23.69M |
| 8 | Corcept Therapeutics Inc. | 4.96% | $23.43M |
| 9 | Gilead Sciences, Inc. | 4.53% | $21.38M |
| 10 | Pfizer Inc. | 4.50% | $21.24M |
| 11 | Amneal Pharmaceuticals, Inc. | 3.75% | $17.69M |
| 12 | Invesco Private Government Fund | 3.73% | $17.63M |
| 13 | Liquidia Corp. | 3.66% | $17.28M |
| 14 | Travere Therapeutics, Inc. | 3.30% | $15.59M |
| 15 | Ligand Pharmaceuticals Inc. | 3.20% | $15.09M |
| 16 | Regeneron Pharmaceuticals, Inc. | 3.14% | $14.84M |
| 17 | Harmony Biosciences Holdings, Inc. | 3.06% | $14.46M |
| 18 | Bristol-Myers Squibb Co. | 2.94% | $13.90M |
| 19 | Viatris Inc. | 2.83% | $13.34M |
| 20 | Jazz Pharmaceuticals PLC | 2.79% | $13.16M |
| 21 | Biogen Inc. | 2.75% | $12.97M |
| 22 | Collegium Pharmaceutical, Inc. | 2.74% | $12.94M |
| 23 | Prestige Consumer Healthcare Inc. | 2.74% | $12.92M |
| 24 | Ocular Therapeutix, Inc. | 2.58% | $12.17M |
| 25 | ANI Pharmaceuticals, Inc. | 2.55% | $12.02M |
Top 25 of 33 holdings, as of Jul 31, 2026. Percentages are of the fund's net assets.
What the fund owns
| Asset type | % of fund |
|---|---|
| Stocks | 99.92% |
| Cash and short-term investments | 11.76% |
| Country | % of fund |
|---|---|
| United States | 106.45% |
| Ireland | 5.24% |
Shares of net assets from the fund's N-PORT report. Funds that borrow can add up to more than 100%, with borrowing (such as repurchase agreements) shown as a negative share.
Monthly total returns
Over the 3 months to Jul 31, 2026, Invesco Pharmaceuticals ETF's total return was +15.78%, as reported to the SEC.
| Month | Total return |
|---|---|
| Jul 31, 2026 | +2.57% |
| Jun 30, 2026 | +8.09% |
| May 31, 2026 | +4.43% |
The fund's own total returns as reported to the SEC (N-PORT), including reinvested distributions. Not the sample prices above.
Fund profile
- Name
- Invesco Pharmaceuticals ETF
- Ticker
- PJP
- Exchange
- ARCA
- Fund type
- ETF
- Trust
- INVESCO EXCHANGE-TRADED FUND TRUST
- SEC series ID
- S000003031
- SEC CIK
- 0001209466
- Fractional shares
- Yes
Recent SEC filings
- Sep 28, 2026
- 485BPOSProspectus updateAug 27, 2026
- Jul 6, 2026
- Jan 5, 2026
- 485BPOSProspectus updateAug 27, 2025
- Jul 3, 2025
- 485BPOSProspectus updateMar 21, 2025
- Jan 3, 2025
Shareholder reports and prospectuses are filed by INVESCO EXCHANGE-TRADED FUND TRUST, the trust behind Invesco Pharmaceuticals ETF, and cover all of its funds.
Frequently asked questions
What is PJP's price?
Invesco Pharmaceuticals ETF (PJP) closed at $588.81 on Oct 9, 2026, down 1.23% from the previous close of $596.16.
What is PJP's expense ratio?
Invesco Pharmaceuticals ETF's expense ratio is 0.57%: $57.00 a year on $10,000 invested.
What does PJP hold?
Invesco Pharmaceuticals ETF held 33 investments worth $472.10M as of Jul 31, 2026. Its largest holding was Invesco Private Prime Fund, at 7.93% of the fund. Its five largest holdings were Invesco Private Prime Fund, Abbott Laboratories, AbbVie Inc., Amgen Inc., Johnson & Johnson.
How has PJP performed?
Over the 3 months to Jul 31, 2026, Invesco Pharmaceuticals ETF's total return was +15.78%, as reported to the SEC.
Sources and methodology
Holdings, net assets and monthly returns come from the fund's N-PORT filing with the SEC, as of Jul 31, 2026 (filed Sep 28, 2026). The expense ratio is from the fund's prospectus or shareholder report, as of Aug 31, 2025. Prices are generated sample data for development. Data sources and disclosures